Natixis Advisors LLC Has $39.34 Million Stock Position in Kenvue Inc. (NYSE:KVUE)

Natixis Advisors LLC raised its position in Kenvue Inc. (NYSE:KVUE) by 3.9% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 1,842,646 shares of the company’s stock after acquiring an additional 69,683 shares during the period. Natixis Advisors LLC owned about 0.10% of Kenvue worth $39,341,000 as of its most recent SEC filing.

Several other large investors have also recently added to or reduced their stakes in KVUE. Los Angeles Capital Management LLC acquired a new position in Kenvue in the 3rd quarter valued at approximately $213,000. Victory Capital Management Inc. grew its stake in shares of Kenvue by 66.2% in the 3rd quarter. Victory Capital Management Inc. now owns 1,328,074 shares of the company’s stock valued at $30,718,000 after purchasing an additional 528,849 shares during the period. Huntington National Bank grew its stake in shares of Kenvue by 26.5% in the 3rd quarter. Huntington National Bank now owns 4,161 shares of the company’s stock valued at $96,000 after purchasing an additional 871 shares during the period. Metis Global Partners LLC grew its stake in shares of Kenvue by 1.5% in the 3rd quarter. Metis Global Partners LLC now owns 61,107 shares of the company’s stock valued at $1,413,000 after purchasing an additional 895 shares during the period. Finally, CIBC Asset Management Inc grew its stake in shares of Kenvue by 4.5% in the 3rd quarter. CIBC Asset Management Inc now owns 435,776 shares of the company’s stock valued at $10,079,000 after purchasing an additional 18,778 shares during the period. Institutional investors and hedge funds own 97.64% of the company’s stock.

Kenvue Stock Down 1.6 %

Shares of KVUE opened at $22.81 on Monday. The firm has a market capitalization of $43.59 billion, a price-to-earnings ratio of 43.03, a PEG ratio of 2.62 and a beta of 1.25. The company has a debt-to-equity ratio of 0.66, a quick ratio of 0.69 and a current ratio of 1.00. The business’s fifty day moving average price is $21.84 and its two-hundred day moving average price is $22.39. Kenvue Inc. has a 52 week low of $17.67 and a 52 week high of $24.46.

Kenvue (NYSE:KVUE) last announced its quarterly earnings data on Thursday, February 6th. The company reported $0.26 EPS for the quarter, meeting analysts’ consensus estimates of $0.26. Kenvue had a return on equity of 20.97% and a net margin of 6.66%. On average, analysts predict that Kenvue Inc. will post 1.14 earnings per share for the current year.

Kenvue Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Wednesday, February 26th. Stockholders of record on Wednesday, February 12th were paid a $0.205 dividend. This represents a $0.82 dividend on an annualized basis and a dividend yield of 3.60%. The ex-dividend date was Wednesday, February 12th. Kenvue’s dividend payout ratio (DPR) is currently 154.72%.

Wall Street Analysts Forecast Growth

KVUE has been the topic of several analyst reports. Citigroup lowered their price objective on Kenvue from $25.00 to $21.00 and set a “neutral” rating on the stock in a research note on Wednesday, January 15th. Royal Bank of Canada reiterated a “sector perform” rating and issued a $24.00 price objective on shares of Kenvue in a research note on Monday, February 3rd. Canaccord Genuity Group upped their price objective on Kenvue from $24.00 to $29.00 and gave the company a “buy” rating in a research note on Wednesday, March 5th. Deutsche Bank Aktiengesellschaft lowered Kenvue from a “buy” rating to a “hold” rating and decreased their price target for the stock from $25.00 to $24.00 in a research report on Thursday, December 12th. Finally, Piper Sandler increased their price target on Kenvue from $24.00 to $27.00 and gave the stock an “overweight” rating in a research report on Monday, February 24th. One equities research analyst has rated the stock with a sell rating, seven have issued a hold rating and five have given a buy rating to the company. Based on data from MarketBeat, the stock has an average rating of “Hold” and a consensus target price of $23.75.

Kenvue Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.